Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

read more

Revolutionary therapies could make spinal muscular atrophy a distant memory

1200 675 Peter Stevenson, PhD

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…

read more

PML risks linked to MS drug duration

1200 797 Peter Stevenson, PhD

Development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is linked to treatment medications, not the MS itself, delegates heard at the recent Consortium of Multiple Sclerosis Centers…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more

First MS treatment approved for children & adolescents

1600 1067 Peter Stevenson, PhD

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

read more

Start MS drugs early, say new guidelines​

1400 885 Peter Stevenson, PhD

Drug therapy for multiple sclerosis (MS) should be started early, according to updated guidelines from the American Academy of Neurology (AAN), which were presented at the recent AAN annual meeting…

read more

Solriamfetol improves wakefulness in narcolepsy patients

1920 1280 Lutz Achtnichts, MD

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

read more

​Huntington’s disease: Antisense drug showing promising results

4288 3216 Lutz Achtnichts, MD

Results from a Phase I/IIa study of IONIS-HTTRx (RG6042) in Huntington’s disease (HD) were presented in a plenary session at the 2018 annual meeting of the American Academy of Neurology (AAN). Results…

read more

​Promising new migraine treatment presented at AAN 2018

5184 3456 Lutz Achtnichts, MD

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…

read more
Multiple Sclerosis

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

1600 1067 Julien Ferrari, PharmD, PhD

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients. You can find the original press…

read more
Brainwork is supported by unrestricted grants from: